Candriam SCA
BLTE icon

Candriam SCA’s Belite Bio BLTE Stock Holding History

Candriam SCA’s Portfolio BLTE Stock Details BLTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$10.7M Buy
+62,842
New +$10.2M 0.05% 264

Other funds holding BLTE

Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
High Net Worth Advisory Group
High Net Worth Advisory Group Naples, Florida $476M AUM 15.5% 1-Year Est. Return
Dymon Asia Capital (Singapore)
Dymon Asia Capital (Singapore) Singapore $2.21B AUM 109.09% 1-Year Est. Return
SmartHarvest Portfolios
SmartHarvest Portfolios Poulsbo, Washington $258M AUM 39.79% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
Vise Technologies
Vise Technologies New York $12B AUM 18.78% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return
EverSource Wealth Advisors
EverSource Wealth Advisors Birmingham, Alabama $3.11B AUM 21.48% 1-Year Est. Return

Candriam SCA's BLTE Position: Q3 2026 in Review

Candriam SCA opened a new position in Belite Bio (BLTE) in Q3 2026: 62,842 shares worth $10.7M. The stake represents 0.05% of the portfolio and ranks #264 among its holdings.

18 funds tracked by Wall St. Rank hold BLTE as of Q3 2026.

  • Candriam SCA held 62,842 shares of Belite Bio worth $10.7M as of Q3 2026.
  • Belite Bio was a new Candriam SCA position in Q3 2026.
  • Belite Bio made up 0.05% of Candriam SCA's portfolio in Q3 2026, its #264 holding.
  • 18 funds tracked by Wall St. Rank held Belite Bio as of Q3 2026.

Based on Candriam SCA's 13F filing for Q3 2026, filed 3 Nov 2026.